Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes

Oncotarget

Volumn 8, Issue 32, 2017, Pages 53028-53040

  Chao, Chia Ter ^a   Wang, Jui ^b   Wu, Hon Yen ^a,b,c,d   Chien, Kuo Liong ^b   Hung, Kuan Yu ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

acute kidney injury; chronic kidney disease; diabetes mellitus; dialysis requiring acute kidney injury; dipeptidyl peptidase 4 inhibitor

Indexed keywords

EID: 85030093299     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.18081     Document Type: Article

References (35)

1. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, et al. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. N Engl J Med. 2011; 364:829-841.
2. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the united states. JAMA. 2011; 305:2532-2539.
3. Gallagher H, Suckling RJ. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab. 2016; 18:641-647.
4. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 298:194-206.
5. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, Matsumoto M, Mizutani K, Park K, Cahill C, Nishikawa S, Rask-Madsen C, King GL. Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes. Diabetes. 2012; 61:2967-2979.
6. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011; 54:965-978.
7. von Websky K, Reichetzeder C, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens. 2014; 23:54-60.
8. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol. 2009; 200:53-61.
9. Hung AM, Roumie CL, Greevy RA, liu X, Grijalva CG, Murff HJ, Ikizler TA, Griffin MR. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012; 81:698-706.
10. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction. Diabetes Care. 2013; 36:3460-3468.
11. Shih CJ, Lee YJ, Lo YH, Kuo SC, Ou SM, Chen YT. Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study. Mayo Clin Proc. 2016; 91:867-872.
12. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis. Am J Kidney Dis. 2010; 55:835-847.
13. Fujita H, Taniai H, Murayama H, Oshiro H, Hayashi H, Sato S, Kikuchi N, Komatsu T, Komatsu K, Komatsu K, Narita T, Yamada Y. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathy. Endocr J. 2014; 61:159-166.
14. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, et al. TECOS Study group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373:232-242.
15. Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M. Renal safety and outcomes with linagliptin: meta-analysis of individual data for 5466 patients with type 2 diabetes. Diabetologia. 2013; 56:S364.
16. Lo Re V, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, Carbonari DM, Hennessy S, Cardillo S, Reese PP, Reddy KR, Margolis D, Apter A, et al. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf. 2012; 21:1202-1215.
17. Baek SH, Kim SH, Kim JW, Kim YJ, Lee KW, Na KY. Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial. Trials. 2015; 16: 239.
18. Harada N, Inagaki N. [Incretin and incretin-based therapies]. [Article in Japanese]. Nihon Rinsho. 2010; 68:931-942.
19. Yang H, Li H, Wang Z, Shi Y, Jiang G, Zeng F. Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat. J Surg Res. 2013; 185:825-832.
20. Girardi AC, Fukuda LE, Rossoni LV, Malnic G, Rebouças NA. Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol. 2008; 294: F414-F422.
21. Chae YN, Kim TH, Kim MK, Shin CY, Jung IH, Sohn YS, Son MH. Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice. PLoS ONE. 2015; 10:e0144064.
22. Mendez CE, Der Mesropian PJ, Mathew RO, Slawski B. Hyperglycemia and Acute Kidney Injury During the Perioperative Period. Curr Diab Rep. 2016; 16: 10.
23. Rajan S, Babazade R, Govindarajan SR, Pal R, You J, Mascha EJ, Khanna A, Yang M, Marcano FD, Singh AK, Kaouk J, Turan A. Perioperative factors associated with acute kidney injury after partial nephrectomy. Br J Anaesth. 2016; 116:70-76.
24. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH. Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. Am J Cardiol. 2012; 110:826-833.
25. Glorie LL, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, D'Haese PC, De Meester I, De Beuf A. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2012; 303: F681-F688.
26. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, et al. N Engl J Med. 2013; 369:1317-1326.
27. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016; 1:126-135.
28. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Pharmacotherapy. 2010; 30:463-484.
29. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone. Diabetes Care. 2006; 29:2638-2643.
30. Siew ED, Basu RK, Wunsch H, Shaw AD, Goldstein SL, Ronco C, Kellum JA, Bagshaw SM, 15th ADQI Consensus Group. Optimizing administrative datasets to examine acute kidney injury in the era of big data: workgroup statement from the 15th ADQI Consensus Conference. Can J Kidney Health Dis. 2016; 3:12.
31. Lin TY, Chen YG, Lin CL, Kao CH. Increased Risk of Acute Kidney Injury following Pneumococcal Pneumonia: A Nationwide Cohort Study. PLoS One. 2016; 11:e0158501.
32. Wu C, Chen Y, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. ASsociation between nucleoside analogues and risk of hepatitis b virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012; 308:1906-1913.
33. Shih CJ, Chen YT, Ou SM, Yang WC, Kuo SC, Tarng DC. The impact of dialysis therapy on older patients with advanced chronic kidney disease: a nationwide population-based study. BMC Med. 2014; 12: 169.
34. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted diabetes complications severity index in claims data. Am J Manag Care. 2012; 18:721-726.
35. Chen HL, Hsiao FY. Risk of hospitalization and healthcare cost associated with diabetes complication severity index in Taiwan's National Health Insurance Research Database. J Diabetes Complications. 2014; 28:612-616.